Back to top
more

Foghorn Therapeutics (FHTX)

(Delayed Data from NSDQ)

$5.49 USD

5.49
35,367

+0.26 (4.97%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $5.49 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know

The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 27.85% and 17.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?

Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why

Foghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%

The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 4.11% and 15.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More

Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -7.35% and 12.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ProPhase Labs, Inc. (PRPH) Soars 7.5%: Is Further Upside Left in the Stock?

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -16.95% and 58.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 161.2% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More

Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -24.53% and 68.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?

Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wall Street Analysts Think Foghorn Therapeutics Inc. (FHTX) Could Surge 85%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 85% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 26%

The consensus price target hints at a 25.6% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.